All types

All types

News

Press releases - Regulatory

Press releases - Non regulatory

All years

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

  • Isofol expands network of advisors with prominent expert

    Non regulatory press release

    GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofol presents at Stora Aktiedagarna on March 12

    Non regulatory press release

    GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that…

  • Isofol presents at several upcoming investor meetings

    Non regulatory press release

    GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that…

  • Isofol Medical AB (publ) publishes year-end report, January – December 2024

    Regulatory press release

    GOTHENBURG, Sweden, February 19, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study

    Non regulatory press release

    GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium

    Non regulatory press release

    GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofol meddelar att en post hoc-analys av fas III-studien AGENT publicerats som abstract vid ASCO-GI 2025

    Non regulatory press release

    GÖTEBORG, Sverige, 27 januari 2025 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) meddelar i…

  • Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan

    Non regulatory press release

    GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports

    Non regulatory press release

    GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol provides an operational update during investor meeting

    Non regulatory press release

    GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide…

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2025

    Regulatory press release

    GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Isofol Medical AB (publ) publishes interim report, January–September 2024

    Regulatory press release

    GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025

    Non regulatory press release

    GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces…

  • Isofol invites to investor meeting on November 20, 2024

    News

    GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today

    Non regulatory press release

    GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024

    Non regulatory press release

    GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol terminates liquidity guarantee agreement

    Regulatory press release

    GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol Medical AB (publ) publishes interim report, January–June 2024

    Regulatory press release

    GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol appoints Margareta Hagman as new Chief Financial Officer

    Regulatory press release

    GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today…

  • Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…

  • Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development

    Regulatory press release

    GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol’s Chief Financial Officer to leave the company

    Regulatory press release

    GOTHENBURG, Sweden, June 12, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…

  • Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024

    Regulatory press release

    Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Isofol Medical AB (publ) publishes interim report, January–March 2024

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023

    Regulatory press release

    GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol Medical AB (publ) offentliggör årsredovisning och bolagsstyrningsrapport för 2023

    Regulatory press release

    GÖTEBORG, Sverige, 16 april 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

    Regulatory press release

    GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Kallelse till årsstämma den 8 maj 2024 i Isofol Medical AB (publ)

    Regulatory press release

    Göteborg, Sverige, 5 april 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), kallar härmed…

  • Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today…

  • Isofols japanska partner Solasia har beslutat att intensifiera sitt engagemang i den kliniska utvecklingen av arfolitixorin

    Regulatory press release

    GÖTEBORG, Sverige, 19 mars 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), meddelar…

  • Isofol presents a clinical development plan for arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today…

  • Isofol presenterar en klinisk utvecklingsplan för arfolitixorin

    Regulatory press release

    GÖTEBORG, Sverige, 19 mars 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), presenterar…

  • Isofol invites to investor meeting on March 19

    News

    GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Isofol bjuder in till investerarmöte den 19 mars

    News

    GÖTEBORG, Sverige, 1 mars 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), bjuder…

  • Isofol Medical AB (publ) publishes year-end report, January – December 2023

    Regulatory press release

    GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar bokslutskommuniké, januari – december 2023

    Regulatory press release

    GÖTEBORG, Sverige, 20 februari 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

    Regulatory press release

    GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been…

  • Isofol appoints Magnus Hurst as new Chief Financial Officer

    Non regulatory press release

    GOTHENBURG, Sweden, January 10, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces…

  • Isofol utser Magnus Hurst till ny Chief Financial Officer

    Non regulatory press release

    GÖTEBORG, Sverige, 10 januari 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Isofol appoints Petter Segelman Lindqvist as new CEO

    Regulatory press release

    GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…

  • Isofol utser Petter Segelman Lindqvist till ny verkställande direktör

    Regulatory press release

    GÖTEBORG, Sverige, 9 januari 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

    Non regulatory press release

    Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm:…

  • Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

    Regulatory press release

    GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…

  • Isofol presenterar ytterligare resultat från laboratorietester med arfolitixorin som visar tilläggseffekter

    Regulatory press release

    GÖTEBORG, Sverige, 28 december 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

    Non regulatory press release

    GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…

  • Isofol has received the first results from laboratory tests of arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…

  • Isofol is liquidating a subsidiary

    Regulatory press release

    GOTHENBURG, Sweden, December 1, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024

    Regulatory press release

    GOTHENBURG, Sweden, November 21, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Isofol Medical AB (publ) publishes interim report, January–September 2023

    Regulatory press release

    GOTHENBURG, Sweden, November 10, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol has obtained a request to call an extraordinary general meeting

    Regulatory press release

    GOTHENBURG, Sweden, November 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained…

  • Isofol har erhållit begäran om att kalla till extra bolagsstämma

    Regulatory press release

    Göteborg, Sverige, 9 november 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) har erhållit…

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2024

    Regulatory press release

    GOTHENBURG, Sweden, November 8, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Isofol har utsett valberedningen inför årsstämman 2024

    Regulatory press release

    GÖTEBORG, Sverige, 8 november 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” eller…

  • Isofol Medical AB (publ) has taken note of the results from the Modelle 001 study

    Non regulatory press release

    GOTHENBURG, Sweden, October 5, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), announces…

  • Isofol Medical AB (publ) har tagit del av resultatet från Modelle 001-studien

    Non regulatory press release

    GÖTEBORG, Sverige, 5 oktober 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Isofol Medical AB (publ) publishes interim report, January–June 2023

    Regulatory press release

    GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar halvårsrapport, januari–juni 2023

    Regulatory press release

    GÖTEBORG, Sverige, 22 augusti 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Isofol presents conclusions from the in-depth analysis of the AGENT study

    Non regulatory press release

    Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from…

  • Isofol’s Board of Directors appoints Roger Tell as acting CEO of the company

    Regulatory press release

    Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board…

  • CEO resigns at his own request in Isofol Medical AB (publ)

    Regulatory press release

    Gothenburg, Sweden, June 21, 2023 – Isofol Medical AB (publ) announces today that Thomas Andersson,…

  • Vd avgår på egen begäran i Isofol Medical AB (publ)

    Regulatory press release

    GÖTEBORG, Sverige, 21 juni 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Changes in the board at Isofol Medical AB (publ)

    Regulatory press release

    Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board…

  • Förändring i styrelsen hos Isofol Medical AB (publ)

    Regulatory press release

    GÖTEBORG, Sverige, 7 juni 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag…

  • Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 3, 2023

    Regulatory press release

    Today on May 3, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Isofol Medical AB (publ) publishes interim report, January–March 2023

    Regulatory press release

    GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar delårsrapport, januari–mars 2023

    Regulatory press release

    GÖTEBORG, Sverige, 3 maj 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS

    Non regulatory press release

    Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Invitation to presentation of Isofol´s report for the first quarter of 2023

    Non regulatory press release

    GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Inbjudan till presentation av Isofols delårsrapport för första kvartalet 2023

    Non regulatory press release

    GÖTEBORG, Sverige, 25 april 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), publicerar…

  • Isofol Medical AB (publ) publishes annual report and corporate governance report for 2022

    Regulatory press release

    GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofols appoints Roy Jonebrant as new acting Chief Financial Officer

    Regulatory press release

    Gothenburg, Sweden, March 17, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofol utser Roy Jonebrant till ny tillförordnad Chief Financial Officer

    Regulatory press release

    GÖTEBORG, 17 mars 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag att…

  • Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin

    Non regulatory press release

    Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofol initierar en stegvis process för den fortsatta utvecklingen av läkemedelskandidaten arfolitixorin

    Non regulatory press release

    GÖTEBORG, 6 mars 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag att…

  • Isofol’s board appoints Thomas Andersson as new CEO of the company

    Regulatory press release

    Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…

  • Isofols styrelse utser Thomas Andersson till ny vd för företaget

    Regulatory press release

    GÖTEBORG, 28 februari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag att…

  • Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 28, 2023

    Regulatory press release

    Today on February 28, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Isofol Medical AB (publ) publishes year-end report, January – December 2022

    Regulatory press release

    GOTHENBURG, Sweden, February 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar bokslutskommuniké, januari – december 2022

    Regulatory press release

    GÖTEBORG, Sverige, 22 februari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 13, 2023

    Regulatory press release

    Today on February 13, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 13 februari 2023

    Regulatory press release

    GÖTEBORG, 13 februari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag att…

  • Invitation to presentation of Isofol´s report for the fourth quarter of 2022

    Non regulatory press release

    GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol has obtained a request to call for an extraordinary general meeting

    Regulatory press release

    GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained…

  • Isofol har erhållit en begäran om att kalla till extra bolagsstämma

    Regulatory press release

    Göteborg, Sverige, 30 januari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) har erhållit…

  • Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting

    Regulatory press release

    GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday…

  • Isofol bjuder in till informationsmöte den 30 januari inför extra bolagsstämma

    Regulatory press release

    GÖTEBORG, Sverige, 20 januari 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), kallade…

  • Notice convening the extraordinary general meeting in Isofol Medical AB (publ) 13 February 2023

    Regulatory press release

    GOTHENBURG, Sweden, January 19, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Kallelse till extra bolagsstämma i Isofol Medical AB (publ) den 13 februari 2023

    Regulatory press release

    Göteborg, Sverige, 19 januari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), kallar härmed…

  • Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company

    Regulatory press release

    GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today…

  • Isofols styrelse avser kalla till extra bolagsstämma med förslag till utdelning och likvidation av bolaget

    Regulatory press release

    GÖTEBORG, Sverige, 19 januari 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) har idag…

  • Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023

    Regulatory press release

    GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial…

  • Isofol Medicals CFO och vice vd Gustaf Albèrt lämnar under 2023

    Regulatory press release

    Göteborg, Sverige, 21 december 2022 – Isofol Medical AB (publ) meddelar idag att bolagets Chief…

  • CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

    Regulatory press release

    GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Final data from the AGENT study confirms topline results

    Regulatory press release

    GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publishes interim report, January–September 2022

    Regulatory press release

    GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2023

    Regulatory press release

    GOTHENBURG, Sweden, November 3, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Invitation to presentation of Isofol’s report for the third quarter of 2022

    Non regulatory press release

    GOTHENBURG, Sweden, October 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Inbjudan till presentation av Isofols delårsrapport för tredje kvartalet 2022

    Non regulatory press release

    GÖTEBORG, Sverige, 27 oktober 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol”), publicerar…

  • Isofol reports data from the AGENT study

    Regulatory press release

    GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported…

  • Isofol redovisar data från AGENT-studien

    Regulatory press release

    GÖTEBORG, Sverige, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) redovisar idag…

  • Isofol provides update on the AGENT study

    Regulatory press release

    GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced…

  • Isofol tillkännager statusuppdatering kring AGENT-studien

    Regulatory press release

    GÖTEBORG, Sverige, 31 augusti 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag…

  • Isofol Medical AB (publ) publishes interim report, January–June 2022

    Regulatory press release

    GOTHENBURG, Sweden, August 23, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar halvårsrapport, januari–juni 2022

    Regulatory press release

    GÖTEBORG, Sverige, 23 augusti 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Invitation to presentation of Isofol´s report for the second quarter of 2022

    Non regulatory press release

    GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints

    Regulatory press release

    GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe

    Non regulatory press release

    GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol updates start time of live-streamed R&D event on June 20 to 14:00 CEST

    Non regulatory press release

    GOTHENBURG, Sweden, June 17, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol invites to a live-streamed R&D Event on June 20 at 12.30 CEST

    Non regulatory press release

    GOTHENBURG, Sweden, June 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol arrangerar livesänt FoU-evenemang den 20 juni kl 12:30

    Non regulatory press release

    GÖTEBORG, Sverige, 14 juni 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) meddelar idag…

  • Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022

    Regulatory press release

    Today on May 19, 2022 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…

  • Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2022

    Regulatory press release

    GÖTEBORG, 19 maj 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelar idag att…

  • Isofol Medical AB (publ) publishes interim report, January–March 2022

    Regulatory press release

    GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) publicerar delårsrapport, januari–mars 2022

    Regulatory press release

    GÖTEBORG, Sverige, 12 maj 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Invitation to presentation of Isofol’s report for the first quarter of 2022

    Non regulatory press release

    GOTHENBURG, Sweden, May 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

    Regulatory press release

    GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol Medical AB (publ) offentliggör årsredovisning och bolagsstyrningsrapport för 2021

    Regulatory press release

    GÖTEBORG, Sverige, 27 april 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), tillkännagav idag…

  • Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer

    Non regulatory press release

    GOTHENBURG, Sweden, April 22, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol påbörjar analysen av studiedata från fas III-studien AGENT inom metastaserad kolorektalcancer

    Regulatory press release

    GÖTEBORG, Sverige, 22 april 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag…

  • Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medical AB (publ)

    Regulatory press release

    GOTHENBURG, Sweden, April 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…

  • Kallelse till årsstämma den 19 maj 2022 i Isofol Medical AB (publ)

    Regulatory press release

    Göteborg, Sverige, 12 april 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), kallar härmed…

  • Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board

    Regulatory press release

    GOTHENBURG, Sweden, April 8, 2022 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq…

  • Isofol Medical AB (publ) valberedning föreslår ny ordförande

    Regulatory press release

    GÖTEBORG, Sverige, 8 april 2022 – Valberedningen i Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL)…

  • Isofol Medical AB (publ) publishes year-end report, January – December 2021

    Regulatory press release

    GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Invitation to presentation of Isofol’s year-end report 2021 on February 24, 2022

    Non regulatory press release

    GOTHENBURG, Sweden, February 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…

  • Isofol recognizes World Cancer Day on February 4

    News

    Today, February 4, is World Cancer Day (https://www.worldcancerday.org/), and we at Isofol are sending our thoughts…

  • Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer

    Non regulatory press release

    GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…

  • Isofol Medical AB (publ) utser Jenny Sundqvist till Chief Commercial Officer (CCO)

    Non regulatory press release

    GÖTEBORG, Sverige, 10 december 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag…

  • Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET

    Non regulatory press release

    GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on…

  • Isofol Medical AB (publ) bjuder in till audiocast den 6 december, klockan 08:00 CET

    Non regulatory press release

    GÖTEBORG, Sverige, 5 december 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), meddelade den…

  • Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

    Regulatory press release

    GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) når inte 300 PFS-händelser i AGENT-studien med nuvarande censureringsregler baserat på FDA-beslut

    Regulatory press release

    GÖTEBORG, Sverige, 3 december 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag…

  • Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

    Regulatory press release

    GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today…

  • Isofol Medical AB (publ) beviljas Fast Track Designation av FDA för arfolitixorin för behandling av avancerad kolorektal cancer

    Regulatory press release

    GÖTEBORG, Sverige, 23 november 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag…

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2022

    Regulatory press release

    GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Isofol Medical AB (publ) publishes interim report for January – September 2021

    Regulatory press release

    GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…

  • Trading in Isofol’s shares commences today on Nasdaq Stockholm

    Non regulatory press release

    GOTHENBURG, Sweden, October 21, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…

  • Handeln i Isofols aktier inleds idag på Nasdaq Stockholm

    Non regulatory press release

    GÖTEBORG, Sverige, 21 oktober 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” eller…

  • Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

    Regulatory press release

    GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol Medical AB (publ) offentliggör prospekt och ny finansiell information i samband med notering på Nasdaq Stockholm

    Regulatory press release

    GÖTEBORG, Sverige, 18 oktober 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm

    Non regulatory press release

    GOTHENBURG, Sweden, October 15, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol Medical AB (publ) avser att notera sina aktier på Nasdaq Stockholm

    Non regulatory press release

    GÖTEBORG, Sverige, 15 oktober 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Company presentation at LSX Nordic Congress 2021

    News

    From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with…

  • Företagspresentation i samband med LSX Nordic Congress 2021

    News

    Den 7-17 september deltog Isofol vid LSX Nordic Congress, ett tillfälle för 1:1-möten med nordiska…

  • Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021

    Regulatory press release

    Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North…

  • Kommuniké från årsstämma i Isofol Medical AB (publ) den 23 juni 2021

    Regulatory press release

    GÖTEBORG, 23 juni 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:…

  • Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

    Regulatory press release

    GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…

  • Isofol offentliggör prospekt i samband med den fullt garanterade företrädesemissionen om cirka 400 miljoner kronor

    Regulatory press release

    GÖTEBORG, Sverige, 25 maj 2021 – Styrelsen i Isofol Medical AB (publ), (Nasdaq First North…

  • Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…

  • Styrelsen i Isofol har beslutat om en fullt garanterad företrädesemission om cirka 400 miljoner kronor

    Regulatory press release

    GÖTEBORG, Sverige, 18 maj 2021 – Styrelsen i Isofol Medical AB (publ), (Nasdaq First North…

  • Isofol completes recruitment of Japanese patients in the global phase III AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq…

  • Isofol slutför rekryteringen av japanska patienter i den globala fas III AGENT-studien

    Non regulatory press release

    GÖTEBORG, Sverige, 6 maj, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

    Regulatory press release

    GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Inbjudan till telefonkonferens och webcast i samband med att Isofol erhåller rekommendation att slutföra den globala fas III AGENT-studien med 440 patienter för ett marknadsgodkännande

    Non regulatory press release

    GÖTEBORG, Sverige, 22 mars 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Regulatory press release

    GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol reaches 440 patients in global Phase III AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    Non regulatory press release

    GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Inbjudan till telefonkonferens och webcast i samband med att Isofol ingår licensavtal med Paladin Labs Inc. för att kommersialisera arfolitixorin i Kanada

    Non regulatory press release

    GÖTEBORG, Sverige, 2 november, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    Regulatory press release

    GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol ingår licensavtal med Paladin Labs Inc. för att kommersialisera arfolitixorin i Kanada

    Regulatory press release

    GÖTEBORG, Sverige, 2 november, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    Non regulatory press release

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Strengthened patent protection for arfolitixorin in Japan

    Non regulatory press release

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Stärkt patentskydd för arfolitixorin i Japan

    Non regulatory press release

    GÖTEBORG, Sverige, 1 september, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    Non regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Inbjudan till telefonkonferens och webcast i samband med det tecknade licensavtalet mellan Isofol och Solasia

    Non regulatory press release

    GÖTEBORG, Sverige, 13 augusti, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    Regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol ingår licensavtal med Solasia för att utveckla och kommersialisera arfolitixorin i Japan

    Regulatory press release

    GÖTEBORG, Sverige, 13 augusti, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…

  • Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

    Non regulatory press release

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth…

  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    Non regulatory press release

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth…

  • AGENT study update with regards to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Uppdatering i AGENT-studien med anledning av covid-19

    Non regulatory press release

    GÖTEBORG, Sverige, 10 juli 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Isofol’s rights issue oversubscribed

    Regulatory press release

    GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…

  • Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

    Non regulatory press release

    GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…

  • Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Information in relation to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, April 2, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Information med anledning av COVID-19

    Non regulatory press release

    GÖTEBORG, 2 april 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:…

  • Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol meddelar sin avsikt att genomföra en fullt garanterad företrädesemission om cirka 150 miljoner kronor och en potentiell övertilldelningsoption om upp till cirka 30 miljoner kronor

    Regulatory press release

    GÖTEBORG, Sverige, 30 mars 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

    Regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…

  • The first patient included in Japan in Isofol’s Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Gene expression analysis method has been validated by a commercial laboratory

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • The Phase 1/2a study ISO-CC-005 is completed

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • The first patient included in Australia in Isofol’s Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL).…

  • Patent godkänt i Japan för Isofols läkemedelskandidat arfolitixorin

    Regulatory press release

    GÖTEBORG, Sverige, 20 december, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL).…

  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    Regulatory press release

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Patentgodkännande i USA för att identifiera hur patienter svarar på folatbaserad cancerbehandling

    Regulatory press release

    GÖTEBORG, Sverige, 13 december, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    Non regulatory press release

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    Regulatory press release

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofols styrelse utser Dr Jarl Ulf Jungnelius som ny vd för företaget

    Regulatory press release

    GÖTEBORG, Sverige, 13 november, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    Non regulatory press release

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 29, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol tillkännager en posterpresentation av den globala fas III-studien med arfolitixorin i metastaserande kolorektal cancer vid ESMO-kongressen 2019

    Non regulatory press release

    Göteborg, Sverige, 29 september 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 12, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Non regulatory press release

    GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol utnämner Roger Tell till Chief Medical Officer (CMO)

    Non regulatory press release

    Göteborg, Sverige, 15 augusti, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    News

    GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol stärker patentportföljen – erhåller Clinical Use Patent i USA för läkemedelskandidaten arfolitixorin

    Regulatory press release

    GÖTEBORG, Sverige, 25 juni 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Election of Three New Board Members

    News

    GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Isofol tillkännager val av tre nya styrelseledamöter

    News

    GÖTEBORG, Sverige, 10 juni 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofols läkemedelskandidat arfolitixorin erhåller Clinical Use Patent i USA

    Regulatory press release

    Göteborg, 21 maj 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), meddelade…

  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

    News

    GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Medical AB (publ) utser Carnegie Investment Bank AB (publ) till finansiell rådgivare

    News

    GÖTEBORG, Sverige, 27 februari 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    News

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol has participated in the Empowered Patient Podcast

    News

    In honor of World Cancer Day on February 4, we would like to share a…

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol rapporterar tumörkrympning hos patienter med spridd kolorektalcancer efter 8 veckors behandling med arfolitixorin

    Regulatory press release

    GÖTEBORG, Sverige, 17 januari 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    Regulatory press release

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    News

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol stärker ledningsgruppen och utnämner Roger Tell, MD, PhD, till Chief Scientific Officer och Senior Vice President of Clinical Development

    News

    Göteborg, Sverige, 19 november, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    News

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol utser Robert Marchesani som rådgivare till bolagets styrelse

    News

    Göteborg, Sverige, 16 november, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    Regulatory press release

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • New Chairman and extended board at Isofol Medical AB (publ)

    Non regulatory press release

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an…

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    The patent now approved in the United States expires in 2037 and covers both the…

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    News

    In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in…

  • Redeye och Isofol bjuder in till direktsändningen av Pre-ASCO den 28 maj

    News

    Inför årets stora cancerkongress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) i Chicago i juni, samlar…

  • Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago

    Regulatory press release

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s…

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    Regulatory press release

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the…

  • Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related…

  • Isofol meddelar att ett abstrakt rörande genetikens inverkan på behandlingsprognos vid CRC-behandling skall presenteras vid ASCO 2018

    Non regulatory press release

    Isofol Medical AB (publ) meddelar att ett abstrakt rörande korrelation mellan expressionsnivåer av folatrelaterade gener…

  • Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    Non regulatory press release

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for…

  • Isofol har valt dos på läkemedelskandidaten arfolitixorin inför registreringsstudien ISO-CC-007

    Non regulatory press release

    Dosen av Isofols läkemedelskandidat arfolitixorin som skall användas i den registreringsgrundande studien ISO-CC-007 ska uppgå…

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) today announce that the company will in the future be adopting…

  • Isofol reports successful outcome from the scientific advice with the EMA

    Regulatory press release

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines…

  • Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    Non regulatory press release

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which…

  • Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Non regulatory press release

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology…

  • Positivt behandlingsutfall med Modufolin® (arfolitixorin) publiceras på cancersymposium (ASCO) i USA

    Non regulatory press release

    Inför årets gastrointestinala (GI) cancer symposium, anordnat av American Society of Clinical Oncology (ASCO),  kommer…

  • Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Regulatory press release

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a…

  • Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from…

  • Isofol tillkännager positiva effektdata för Modufolin® (arfolitixorin) hos patienter som behandlas för metastaserande kolorektalcancer

    Non regulatory press release

    Isofol Medical AB (publ), ett kliniskt onkologibolag, tillkännager idag positiva effektdata för Modufolin® (arfolitixorin) hos…

  • Isofol to present at the 10th Annual Biotech Showcase Conference

    Non regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe…

  • Isofol kommer presentera på årets uppsättning av Biotech Showcase Conference i San Fransisco

    Non regulatory press release

    Isofol Medical AB (publ), ett kliniskt onkologibolag, meddelar att Chief Executive Officer Anders Rabbe och…

  • Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    News

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment…

  • ­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Non regulatory press release

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience…

  • Isofol utser Gustaf Albèrt till Chief Financial Officer

    Non regulatory press release

    Isofol Medical AB (publ) har rekryterat Gustaf Albèrt till positionen som Chief Financial Officer. Med…

  • Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Regulatory press release

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin®…

  • Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA…

  • From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin®…

  • Isofol meddelar att initiala resultat från pågående studien ISO-CC-005 indikerar effekt av Modufolin® vid behandling av metastaserad kolorektalcancer

    Non regulatory press release

    Isofol Medical AB (publ), ett klinisk onkologibolag, meddelar att lovande initiala resultat från ISO-CC-005 studien…

  • Isofols appoints Sven Erickson as Chief Commercial Officer

    Non regulatory press release

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment…

  • Isofol utser Dr. Sven Erickson till Chief Commercial Officer

    Non regulatory press release

    Som del av förberedelserna inför diskussioner med potentiella partners meddelar Isofol Medical AB (publ) utnämningen…

  • Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Non regulatory press release

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal…

  • Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be…

  • Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

    Non regulatory press release

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed…

  • Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed…

  • New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Regulatory press release

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results…

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    Non regulatory press release

    Isofol Medical AB (publ) announced today that the last one of five additional study sites…

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue…

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

     In connection with the offering to acquire newly issued shares in Isofol and the listing…

  • Pareto Securities har meddelat Isofol Medical AB att stabiliseringsåtgärder avseende Bolagets aktier har vidtagits

    Regulatory press release

    I samband med erbjudandet att förvärva nyemitterade aktier i Isofol och noteringen på Nasdaq First…

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    Non regulatory press release

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at…

  • Isofol godkänt för presentation av abstract på årets ASCO-kongress

    Non regulatory press release

    Isofol Medical AB (publ) meddelar att ett abstract har godkänts för att presenteras på årets…

  • Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken

    Regulatory press release

    In connection with the offering to acquire newly issued shares in Isofol and the listing…

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

    Non regulatory press release

    For a complete press release follow the link http://isofol.se/en/ipo/  For additional information, please contact: Anders Rabbe, Managing…

  • Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Non regulatory press release

    Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after…

  • Isofol’s largest shareholder and co-founder acquires shares in the company

    Non regulatory press release

    Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now…

  • Isofol’s Chairman of the Board acquires shares in the company

    Non regulatory press release

    Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired…

  • Isofols Styrelseordförande förvärvar aktier i bolaget

    Non regulatory press release

    Isofol Medical AB (publ) meddelar idag att dess Styrelseordförande, Jan-Eric Österlund, förvärvat 15 000 aktier…

  • Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

    Regulatory press release

    Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of…

  • Isofol Medical offentliggör utfallet av Erbjudandet – handel på Nasdaq First North Premier inleds idag

    Regulatory press release

    Isofol Medical AB (publ), ett läkemedelsbolag i klinisk fas, offentliggör härmed att erbjudandet avseende teckning…

  • Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29

    Non regulatory press release

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22

    Non regulatory press release

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • Inbjudan: Isofol kommer presentera sin planerade börsnotering i Göteborg 22 mars

    Non regulatory press release

    I samband med den planerade börsnoteringen av Isofol Medical på Nasdaq First North Premier vill vi…

  • Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

    Non regulatory press release

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…

  • Notering av Isofol Medical på Nasdaq First North Premier och offentliggörande av prospekt

    Non regulatory press release

    EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, Australien, Kanada,…

  • Isofol announces its intention to list on Nasdaq First North Premier

    Non regulatory press release

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…

  • ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION

    Non regulatory press release

    Isofol Medical AB (publ) today announces that a new patent application was filed, on February…

  • FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®

    Non regulatory press release

    Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s…

  • ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING

    Non regulatory press release

    Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was…

  • ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.

    Non regulatory press release

    Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination…

  • ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®

    Non regulatory press release

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within…

Scroll to Top